Mersana Therapeutics (MRSN)
(Delayed Data from NSDQ)
$6.70 USD
-0.34 (-4.83%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $6.65 -0.05 (-0.75%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Mersana Therapeutics, Inc. has a market cap of $35.10M, which represents its share price of $7.04 multiplied by its outstanding shares number of 4.99M. As a small-cap company, MRSN's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
MRSN 6.70 -0.34(-4.83%)
Will MRSN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MRSN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRSN
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates
Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates
MRSN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
Other News for MRSN
Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025 | MRSN ...
Mersana Therapeutics trading halted, news pending
MRSN Trading Halted Due to Pending News
Mersana Therapeutics Announces 1-for-25 Reverse Stock Split | MRSN Stock News
Mersana Therapeutics (MRSN) Implements 1-for-25 Reverse Stock Split | MRSN Stock News